Gregory L. Beatty, MD, PhD, brings his insight to a comprehensive overview of cancer immunotherapy, beginning with the fundamental laws of the immune system and incorporating the challenges for immunotherapy, efforts to restore T cell immune-surveillance, checkpoint immunotherapy in melanoma and other cancers, biomarkers of cancer immunogenicity, CAR T cells in cancer and the future for cancer immunotherapy. Dr. Beatty led the first clinical study of CD40 immunotherapy for pancreas cancer, the first in-human study of a novel inhibitor of indoleamine 2,3 deoxygenase, and is currently working to translate novel T cell adoptive therapies for pancreas cancer.
Related Links
- Enrolling Clinical Trials: Adoptive Immunotherapy for Chemotherapy Resistant or Refractory CD-19+ Leukemia and Lymphoma
- Case Study: A 65-year-old male diagnosed with CLL and refractory to purine analogs following six courses of treatment opts for the CTL019 treatment regimen when his lab work reveals a white count of 30,000, extensive marrow infiltration and diffuse
- Dr. Beatty’s Profile
Published
December 23, 2015
Created by
BROADCASTMED